NASDAQ:AVCO Avalon GloboCare (AVCO) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free AVCO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.38▼$0.7052-Week Range N/AVolume441,100 shsAverage Volume142,644 shsMarket Capitalization$52.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Avalon GloboCare alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Avalon GloboCare Stock (NASDAQ:AVCO)Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. AVCO Stock News HeadlinesSeptember 13, 2023 | markets.businessinsider.comAvalon’s Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter DeviceSeptember 5, 2023 | markets.businessinsider.comAvalon GloboCare Announces Notice of Publication for Key U.S. Patent Filed Jointly with the Massachusetts Institute of Technology (MIT)April 25, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.August 30, 2023 | finance.yahoo.comAvalon’s Laboratory Services MSO Launches Innovative Laboratory Test for TuberculosisJuly 24, 2023 | finance.yahoo.comAvalon’s Laboratory Services MSO Acquires Texas Lab with Significant Potential GrowthApril 22, 2023 | investing.comAvalon Globocare Corp (ALBT)March 3, 2023 | finance.yahoo.comAvalon GloboCare to Participate in the 35th Annual Roth ConferenceMarch 1, 2023 | detroitnews.comAvalon reopens in Midtown on Canfield Wednesday with 25 cent cookiesApril 25, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.November 9, 2022 | finance.yahoo.comAvalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”November 8, 2022 | proactiveinvestors.comAvalon Globocare enters 'transformative' deal to acquire majority stake in Laboratory Services MSONovember 8, 2022 | proactiveinvestors.comBiotech junior climbs on acquisition deal: Proactive’s daily small cap moversNovember 8, 2022 | seekingalpha.comAvalon GloboCare to acquire a 60% interest in Laboratory Services MSO, LLCNovember 8, 2022 | proactiveinvestors.comAvalon GloboCare to acquire majority interest in Laboratory Services MSO in 'transformative' deal worth $31MNovember 8, 2022 | finance.yahoo.comEXCLUSIVE: Avalon GloboCare Acquires Majority Stake In Premier Reference LaboratoryNovember 8, 2022 | finance.yahoo.comAvalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 MillionNovember 8, 2022 | finance.yahoo.comInvestors in Avalon GloboCare (NASDAQ:AVCO) from five years ago are still down 72%, even after 32% gain this past weekOctober 19, 2022 | finance.yahoo.comAvalon Globocare to Present at the LD Micro Main Event XV on October 26thSeptember 29, 2022 | proactiveinvestors.comAvalon GloboCare gets notice of allowance from US patent office for QTY fusion platformSeptember 29, 2022 | finance.yahoo.comAvalon GloboCare Receives Allowance for Joint U.S. PatentSeptember 16, 2022 | seekingalpha.comAVCO Avalon GloboCare Corp.September 10, 2022 | uk.finance.yahoo.comAvalon GloboCare Corp. (AVCO)September 9, 2022 | nasdaq.comInvestors in Avalon GloboCare (NASDAQ:AVCO) have unfortunately lost 82% over the last five yearsAugust 8, 2022 | proactiveinvestors.comAvalon GloboCare says its co-developed QTY code protein code technology featured in Chemical ReviewsAugust 8, 2022 | finance.yahoo.comAvalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical SocietyJune 30, 2022 | ca.proactiveinvestors.comAvalon GloboCare reveals new study using AI-powered protein design technology targeting glucose transporter against cancerJune 30, 2022 | finance.yahoo.comAvalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against CancerSee More Headlines Receive AVCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalon GloboCare and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2018Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Management consulting services Sub-IndustryN/A Current SymbolNASDAQ:AVCO CUSIPN/A CIK1630212 Webwww.avalon-globocare.com Phone(732) 780-4400Fax732-780-5600Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,090,000.00 Net Margins-599.86% Pretax Margin-599.79% Return on Equity-444.65% Return on Assets-70.05% Debt Debt-to-Equity Ratio14.00 Current Ratio0.23 Quick Ratio0.23 Sales & Book Value Annual Sales$1.39 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / BookN/AMiscellaneous Outstanding Shares99,215,000Free Float28,872,000Market Cap$52.18 million OptionableNot Optionable Beta0.81 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. David K. Jin M.D. (Age 54)Ph.D., CEO, Pres & Director Comp: $360kMs. Luisa Ingargiola (Age 55)Chief Financial Officer Comp: $350kMs. Meng Li (Age 44)COO, Sec. & Director Comp: $340kKey CompetitorsAeries TechnologyNASDAQ:AERTInformation Services GroupNASDAQ:IIICXAppNASDAQ:CXAIuCloudlink GroupNASDAQ:UCLPono CapitalNASDAQ:PONOView All Competitors AVCO Stock Analysis - Frequently Asked Questions How were Avalon GloboCare's earnings last quarter? Avalon GloboCare Corp. (NASDAQ:AVCO) posted its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $0.41 million for the quarter. Avalon GloboCare had a negative net margin of 599.86% and a negative trailing twelve-month return on equity of 444.65%. What other stocks do shareholders of Avalon GloboCare own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avalon GloboCare investors own include Amarin (AMRN), Axsome Therapeutics (AXSM), Clovis Oncology (CLVS), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV), Exxon Mobil (XOM), Intercept Pharmaceuticals (ICPT), Occidental Petroleum (OXY), REGENXBIO (RGNX) and Adamis Pharmaceuticals (ADMP). This page (NASDAQ:AVCO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.